In conclusion, our study demonstrates that FDA-approved PDE4 inhibitors, including Roflumilast and Apremilast, can effectively mitigate the morphological and functional mitochondrial defects induced by the CHCHD10S59L mutation associated with ALS-FTD. Here, PDE4A is linked to amyotrophic lateral sclerosis.